- Email: [email protected]
New Borrelia burgdorferi polypeptide; associated with highly infective strains used for detection of Lyme disease and in vaccine
Vaccine,Vol.
13, No. 12, p. 1139, 1995 Copyright 0 1995 Elsevier Science Ltd Printed in Great Britain. All rights reserved 0264-41OW95 $iO+O.OO
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from ‘Biotechnology Abstracts’ with permission of Derwent Information Ltd, Derwent House, 14 Great Queen Street, London WC2B 5DF. polypeptide; associated with highly infective strains used for detection of Lyme disease and in vaccine Univ. Texas-Syst
New Borrelia burghrferi
World 9508 568; 30 March 1995 A polypeptide is claimed which has a mol.wt of 38 000 as determined by two-dimensional gel electrophoresis and which is produced in infectious Borrelia burgdorferi (Bb). Also disclosed are other Bb polypeptides (particularly 30 kDa) and nucleic acids encoding the polypeptides. More specifically, Bb is strain Sh2 (5A3, 5A4 or 5A5). The polypeptide is used for the production of vaccines and in the production of antibodies and for detection. In particular, detection of the presence of antibodies to the polypeptide in the blood of subjects can be used for detecting the presence of Lyme disease. The 38 kDa polypeptide is found only in highly infective Bb strains and not in low infective Bb strains and can provide selective and sensitive assays for Lyme disease and effective vaccines. 049-95 strain CVD103 Hgr; deletion mutant construction with mercury-resistance using e.g. vector plasmid pJBK55, for application as a cholera recombinant vaccine Univ. Maryland
New F’ibvio cholerue
USA 5399 494; 21 March 1995 The following are claimed: (1) Vibrio cholerae CVD103hgr (ATCC 55456); and (2) a culture of ATCC 55456. Also claimed is a method of isolating deletion mutants of V. cholerae Inaba which involves: constructing a plasmid (e.g. plasmid pJBK55) composed of V. chokrae flanking sequences of the gene encoding the Al subunit of V. cholerae toxin and a gene encoding a selectable marker (Sm); mating virulent V. cholerae 569B with a microorganism carrying the above plasmid; selecting I! cholerae expressing the Sm; mating the selected product with a second microorganism carrying a second plasmid with a second Sm; selecting V. cholerae expressing both the first and second Sm; mating the in vivo recombinant V. choZerae with a third microorganism carrying a third plasmid composed of flanking sequences of a sequence encoding the Al subunit of V. cholerae toxin; selecting for the loss of the first Sm; mating the selected product with a fourth microorganism carrying a fourth plasmid encoding a gene conferring mercury-resistance; and selecting V. cholerae expressing the gene conferring mercury-resistance. The V. cholerae deletion mutants are useful for vaccination against cholera. 050-95 New nucleic acid encoding tagA antigen of Helicobacter pylori; used to detect predisposition to peptic ulceration and to produce protein for use in vaccine, diagnosis, etc. Univ. Vanderbilt USA 5403 924; 4 April 1995 Isolated nucleic acid consists (compound I) of nucleotides 1072-3648 of a 3648 bp sequence or (compound II) nucleotides 10724614 of a 4821 bp sequence. Both sequences are specified, together with derived proteins (859 and 1181 amino acids).
Also new are: i. vectors containing (I) and (II); and ii. host cells containing these vectors and able to express proteins encoded by (I) and (II). (II) preferably contains the complete open reading frame for the tagA antigen which (I) encodes a truncated version. A wider disclosure includes: a. antigens expressed by (I) and (II); b. antibodies raised against these antigens; c. mutant H. pylori in which the tagA protein has been rendered non-functional (e.g. by introducing a substitution mutation). (I) and (II) (or probes from them) can be used to detect DNA encoding the Helicobacter pylori 12G128 kDa antigen (tagA) that is associated with toxin production and thus predisposition to development of peptic ulcers, and to produce full-length or truncated tagA protein. TagA proteins may be used as vaccine components (to protect against ulceration, atrophic gastritis and stomach neoplasms). 051-95 New modified forms of pertussis holotoxin; recombinant pertussis toxin production by site-directed mutagenesis and expression iu Bordetellu sp. for use in recombinant vaccine construction Connaught; Univ. Alberta
Eur 646 599; 5 April 1995 A new method for predicting at least one site (St) contributing to the biological activity of pertussis holotoxin (I) involves analysing a three-dimensional structure of crystalline (I) determined by X-ray crystallography in relation to known information concerning protein structure and function to identify the St. Also new are: a method for identifying at least one side in (I) that interacts with a molecule that is capable of forming a complex with (I); use of a 3-D structure of crystalline (I) for identifying St in (I) contributing to the biological activity; crystalline (I); a method for producing modified (I) involving identifying at least one amino acid residue of (I) for modification (residue 184-203 or 21 l-220) by analysing a 3-D structure of crystalline (I), effecting mutagenesis of a tox operon encoding (I) to remove or replace a nucleotide sequence encoding at least one amino acid residue and to produce a mutant tox operon, and expressing the mutant tox operon in Bordetella sp.; a mutant (I) with at least one amino acid residue in the Sl, S2, S3, S4 or S5 subunits detailed or substituted by another amino acid residue. The crystalline (I) are very pure. 052-95 Attenuated Salmonella live vaccine strain sensitive to macrolide antibiotics; with extended generation times, especially used to immunize fowl chicks or adult hens TAD Pharm
Eur 642 796; 15 March 1995 Use of at least one attenuated, immunogenic Salmonella live vaccine strain, provided with a marker (envelope marker) that imparts sensitivity to macrolide antibiotics (I), to prepare a live vaccine for a particular host, is new. In the event that the strain infects a different host, then the second host may be effectively treated with (I). Also claimed are: i. live Salmonella vaccines consisting of strains as above in which the envelope marker imparts sensitivity to a second antibiotic other than (optionally in addition to) (I); and ii. Salmonella vaccine strains having generation times of 31-32 min. The vaccines are used to immunise fowl chicks, orally, and/or parenterally or as a booster. These vaccine strains have optimum attenuation for immunization and impart immunity that reduces the excretion of wild-type bacteria and represent little, if any, danger to humans (including immune deficient subjects). They can be identified by a procedure that involves fewer animal tests than usual. 053-95
Vaccine 1995 Volume 13 Number 12 1139
13, No. 12, p. 1139, 1995 Copyright 0 1995 Elsevier Science Ltd Printed in Great Britain. All rights reserved 0264-41OW95 $iO+O.OO
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from ‘Biotechnology Abstracts’ with permission of Derwent Information Ltd, Derwent House, 14 Great Queen Street, London WC2B 5DF. polypeptide; associated with highly infective strains used for detection of Lyme disease and in vaccine Univ. Texas-Syst
New Borrelia burghrferi
World 9508 568; 30 March 1995 A polypeptide is claimed which has a mol.wt of 38 000 as determined by two-dimensional gel electrophoresis and which is produced in infectious Borrelia burgdorferi (Bb). Also disclosed are other Bb polypeptides (particularly 30 kDa) and nucleic acids encoding the polypeptides. More specifically, Bb is strain Sh2 (5A3, 5A4 or 5A5). The polypeptide is used for the production of vaccines and in the production of antibodies and for detection. In particular, detection of the presence of antibodies to the polypeptide in the blood of subjects can be used for detecting the presence of Lyme disease. The 38 kDa polypeptide is found only in highly infective Bb strains and not in low infective Bb strains and can provide selective and sensitive assays for Lyme disease and effective vaccines. 049-95 strain CVD103 Hgr; deletion mutant construction with mercury-resistance using e.g. vector plasmid pJBK55, for application as a cholera recombinant vaccine Univ. Maryland
New F’ibvio cholerue
USA 5399 494; 21 March 1995 The following are claimed: (1) Vibrio cholerae CVD103hgr (ATCC 55456); and (2) a culture of ATCC 55456. Also claimed is a method of isolating deletion mutants of V. cholerae Inaba which involves: constructing a plasmid (e.g. plasmid pJBK55) composed of V. chokrae flanking sequences of the gene encoding the Al subunit of V. cholerae toxin and a gene encoding a selectable marker (Sm); mating virulent V. cholerae 569B with a microorganism carrying the above plasmid; selecting I! cholerae expressing the Sm; mating the selected product with a second microorganism carrying a second plasmid with a second Sm; selecting V. cholerae expressing both the first and second Sm; mating the in vivo recombinant V. choZerae with a third microorganism carrying a third plasmid composed of flanking sequences of a sequence encoding the Al subunit of V. cholerae toxin; selecting for the loss of the first Sm; mating the selected product with a fourth microorganism carrying a fourth plasmid encoding a gene conferring mercury-resistance; and selecting V. cholerae expressing the gene conferring mercury-resistance. The V. cholerae deletion mutants are useful for vaccination against cholera. 050-95 New nucleic acid encoding tagA antigen of Helicobacter pylori; used to detect predisposition to peptic ulceration and to produce protein for use in vaccine, diagnosis, etc. Univ. Vanderbilt USA 5403 924; 4 April 1995 Isolated nucleic acid consists (compound I) of nucleotides 1072-3648 of a 3648 bp sequence or (compound II) nucleotides 10724614 of a 4821 bp sequence. Both sequences are specified, together with derived proteins (859 and 1181 amino acids).
Also new are: i. vectors containing (I) and (II); and ii. host cells containing these vectors and able to express proteins encoded by (I) and (II). (II) preferably contains the complete open reading frame for the tagA antigen which (I) encodes a truncated version. A wider disclosure includes: a. antigens expressed by (I) and (II); b. antibodies raised against these antigens; c. mutant H. pylori in which the tagA protein has been rendered non-functional (e.g. by introducing a substitution mutation). (I) and (II) (or probes from them) can be used to detect DNA encoding the Helicobacter pylori 12G128 kDa antigen (tagA) that is associated with toxin production and thus predisposition to development of peptic ulcers, and to produce full-length or truncated tagA protein. TagA proteins may be used as vaccine components (to protect against ulceration, atrophic gastritis and stomach neoplasms). 051-95 New modified forms of pertussis holotoxin; recombinant pertussis toxin production by site-directed mutagenesis and expression iu Bordetellu sp. for use in recombinant vaccine construction Connaught; Univ. Alberta
Eur 646 599; 5 April 1995 A new method for predicting at least one site (St) contributing to the biological activity of pertussis holotoxin (I) involves analysing a three-dimensional structure of crystalline (I) determined by X-ray crystallography in relation to known information concerning protein structure and function to identify the St. Also new are: a method for identifying at least one side in (I) that interacts with a molecule that is capable of forming a complex with (I); use of a 3-D structure of crystalline (I) for identifying St in (I) contributing to the biological activity; crystalline (I); a method for producing modified (I) involving identifying at least one amino acid residue of (I) for modification (residue 184-203 or 21 l-220) by analysing a 3-D structure of crystalline (I), effecting mutagenesis of a tox operon encoding (I) to remove or replace a nucleotide sequence encoding at least one amino acid residue and to produce a mutant tox operon, and expressing the mutant tox operon in Bordetella sp.; a mutant (I) with at least one amino acid residue in the Sl, S2, S3, S4 or S5 subunits detailed or substituted by another amino acid residue. The crystalline (I) are very pure. 052-95 Attenuated Salmonella live vaccine strain sensitive to macrolide antibiotics; with extended generation times, especially used to immunize fowl chicks or adult hens TAD Pharm
Eur 642 796; 15 March 1995 Use of at least one attenuated, immunogenic Salmonella live vaccine strain, provided with a marker (envelope marker) that imparts sensitivity to macrolide antibiotics (I), to prepare a live vaccine for a particular host, is new. In the event that the strain infects a different host, then the second host may be effectively treated with (I). Also claimed are: i. live Salmonella vaccines consisting of strains as above in which the envelope marker imparts sensitivity to a second antibiotic other than (optionally in addition to) (I); and ii. Salmonella vaccine strains having generation times of 31-32 min. The vaccines are used to immunise fowl chicks, orally, and/or parenterally or as a booster. These vaccine strains have optimum attenuation for immunization and impart immunity that reduces the excretion of wild-type bacteria and represent little, if any, danger to humans (including immune deficient subjects). They can be identified by a procedure that involves fewer animal tests than usual. 053-95
Vaccine 1995 Volume 13 Number 12 1139